STOCK TITAN

Nexgel Inc Wt Exp 120126 Stock Price, News & Analysis

NXGLW Nasdaq

Welcome to our dedicated page for Nexgel Wt Exp 120126 news (Ticker: NXGLW), a resource for investors and traders seeking the latest updates and insights on Nexgel Wt Exp 120126 stock.

NexGel Inc (NXGLW) develops advanced hydrogel solutions for medical and cosmetic applications through proprietary electron beam cross-linking technology. This dedicated news hub provides investors and industry professionals with essential updates on the company’s innovations in wound care systems, transdermal delivery platforms, and material science breakthroughs.

Access timely announcements including regulatory milestones, strategic partnerships, product developments, and financial performance. Our curated collection ensures efficient tracking of NXGLW’s progress across key sectors: FDA-cleared medical devices, OTC hydrogel products, and custom manufacturing solutions for healthcare providers.

Discover press releases covering technical achievements, manufacturing expansions, and clinical application studies. All content is verified for accuracy and relevance to support informed analysis of NexGel’s market position in the competitive hydrogel industry.

Bookmark this page for centralized access to NXGLW’s material developments, presented with clarity for both technical experts and general investors. Regularly updated to reflect the company activities shaping next-generation hydrogel applications.

Rhea-AI Summary

NEXGEL, Inc. has launched a new hydrogel dressing called Turfguard, targeted for athletes to soothe turf burns and protect against infections. Approved by the FDA, Turfguard patches are designed to kill 99% of harmful bacteria, including staph, MRSA, and strep. These patches maintain a moist healing environment and provide cooling relief, making them ideal for treating superficial wounds in sports settings. Manufactured in Langhorne, Pa., Turfguard is now available for purchase on Amazon.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
none
-
Rhea-AI Summary

NEXGEL reported a 69.6% year-over-year revenue increase for Q3 2022, totaling $568,000. The gross profit margin improved to 26%, up from a loss the previous year. Cash and equivalents stand at $7.4 million, ensuring operational stability through 2024. The company launched new products and reported positive results from a diclofenac hydrogel study. Despite increased operating expenses, particularly in R&D and SG&A, NEXGEL expects continued revenue and margin growth into 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-46.39%
Tags
-
Rhea-AI Summary

NEXGEL (NASDAQ: NXGL) will report its third quarter 2022 financial results after market close on November 8, 2022. Following the results, a conference call will be held at 4:30 P.M. ET, which will be accessible via live webcast on NEXGEL's Investor Relations website. A replay will be available until November 15, 2022.

NEXGEL specializes in high-water-content hydrogel products for health and consumer applications and has developed over 200 formulations for gentle skin patches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary

NEXGEL (NASDAQ: NXGL, NXGLW) announced positive outcomes from its proof-of-concept study on diclofenac hydrogel patches, aimed at treating pain including arthritis and muscle aches. The study showed that NEXGEL's patches delivered pain relief faster and were longer-acting compared to the leading treatment. These patches adhered to the skin gently for 8-12 hours. CEO Adam Levy expressed optimism about the product's potential and plans for human clinical studies, while seeking strategic partnerships for future development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
Rhea-AI Summary

NEXGEL (NASDAQ: NXGL, NXGLW) announced the development of a new proprietary hydrogel eye patch to treat amblyopia, commonly known as lazy eye. The patch, expected to be available in the first half of 2023, aims to provide a gentler alternative to traditional eye patches, which can irritate sensitive skin. Amblyopia affects approximately 2-4% of the U.S. population and the global treatment market is projected to exceed $6 billion by 2027. This innovation highlights NEXGEL's commitment to enhancing pediatric care while meeting a growing market demand.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

NEXGEL, a provider of high-water-content hydrogel products, announced CEO Adam Levy's participation in two upcoming conferences: the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022, in Jupiter, Florida, and the LD Micro Main Event XV from October 25-27, 2022, in Los Angeles, California. Levy will speak at the LD Micro conference on October 26 at 8:30 AM PT. Interested investors can schedule 1x1 meetings through their respective representatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

NEXGEL has announced promising results from a study published in SAGE Journals regarding its SilverSeal hydrogel dressing. The study involved 40 foot and ankle patients and evaluated post-surgical scarring and complications. Results showed that patients using SilverSeal experienced significant improvements in scar quality, reduced pain, and lower itching at the surgical site compared to those with a standard petroleum-based dressing. No postoperative complications were reported in either group, suggesting SilverSeal's potential in enhancing surgical recovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
none
-
Rhea-AI Summary

NEXGEL, Inc. (NASDAQ: NXGL, NXGLW) has appointed Dr. Neil Chesen and Dr. Leonard Nelson to its Scientific Advisory Board. Dr. Nelson is a pediatric ophthalmology leader with extensive credentials, including roles at Wills Eye Hospital and Thomas Jefferson University. Dr. Chesen is a seasoned ophthalmologist with over 33 years of experience. Their addition aims to enhance NEXGEL's development of high-water-content hydrogel products for healthcare applications. CEO Adam Levy emphasized that their expertise will significantly aid in advancing the company's innovative hydrogel solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

NEXGEL, Inc. (NASDAQ: NXGL, NXGLW) announced that CEO Adam Levy will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022. The presentation is scheduled for September 14, from 9:00 A.M. to 9:30 A.M. Eastern Time. Interested investors can contact their H.C. Wainwright representative or email NEXGEL@kcsa.com for 1x1 meetings. NEXGEL specializes in high-water-content hydrogel products for healthcare and consumer applications, having over two decades of experience in developing these innovative solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences
Rhea-AI Summary

NEXGEL reported a 35% year-over-year revenue growth to $561 thousand for Q2 2022, showing a 42% sequential increase. The rise is attributed to successful launches and demand for branded products, such as MEDAGEL Pro Pads. Gross profit improved to $101 thousand, with an 18% margin. However, operating expenses rose to $819 thousand, driven by increased R&D investments and higher SG&A costs. As of June 30, 2022, cash and equivalents stood at $9.7 million, ensuring a solid financial position for ongoing growth initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags

FAQ

What is the current stock price of Nexgel Wt Exp 120126 (NXGLW)?

The current stock price of Nexgel Wt Exp 120126 (NXGLW) is $0.309 as of September 22, 2025.
Nexgel Inc Wt Exp 120126

Nasdaq:NXGLW

NXGLW Rankings

NXGLW Stock Data

2.07M
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
LANGHORNE